Showing 641 - 660 results of 27,762 for search '(( 100 ((ng decrease) OR (nn decrease)) ) OR ( 50 ((mean decrease) OR (a decrease)) ))', query time: 0.73s Refine Results
  1. 641
  2. 642
  3. 643

    Decreased E/I synapse ratio and loss of cortico-LA synaptic plasticity in the absence of coronin 1. by Rajesh Jayachandran (542641)

    Published 2014
    “…Strong cortico-LA LTP was induced in wild-type [WT (grey symbols), <i>n</i> = 12, <i>p</i><0.05 versus baseline, <i>p</i><0.05 versus Cor 1 −/− (red symbols), Student's <i>t</i> test), but not in coronin 1–deficient mice [Cor 1 −/− (red), <i>n</i> = 7, <i>p</i>>0.05 versus baseline, Student's <i>t</i> test]. Scale bars, 50 pA and 20 ms. (G) Synaptic transmission and PPR in wild-type (left) and coronin 1–deficient mice (right) in the presence of forskolin. …”
  4. 644
  5. 645
  6. 646
  7. 647
  8. 648
  9. 649
  10. 650
  11. 651

    Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation. by David W. Donley (3111198)

    Published 2021
    “…<p>Mouse pups were supplemented with carbonyl iron from postnatal days 10–17 and then were sacrificed at 14 weeks of age. <b>A.</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …”
  12. 652
  13. 653

    Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

    Published 2016
    “…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”
  14. 654
  15. 655

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  16. 656

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  17. 657

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  18. 658
  19. 659

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  20. 660